Investment Considerations HeartBeam has developed and secured FDA clearance for a credit card-sized synthesized 12-Lead ECG device that enables arrhythmia assessment outside of traditional clinical settings. The company’s 12-lead ECG synthesis software successfully met pivotal study endpoints and received FDA 510(k) clearance for arrhythmia assessment in December 2025, enabling initial commercialization. HeartBeam is advancing AI-driven … Continue reading “HeartBeam Inc. (NASDAQ: BEAT)”
| Symbol | Release | Time |
|---|---|---|
| {{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |